Actinogen Medical Valuation Multiples

Actinogen Medical Overview

About Actinogen Medical

Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.

Founded

1999

HQ

Employees

N/A

Website

actinogen.com.au

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $3M

EBITDA: ($13M)

EV

$92M

Valuation Multiples

Multiples.vc

Start free trial

Actinogen Medical Financials

Actinogen Medical reported last 12-month revenue of $3M and negative EBITDA of ($13M).

In the same LTM period, Actinogen Medical generated $3M in gross profit, ($13M) in EBITDA losses, and had net loss of ($13M).

Actinogen Medical P&L

In the most recent fiscal year, Actinogen Medical reported revenue of — and net income of —.

Actinogen Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX

Actinogen Medical Stock Performance

Actinogen Medical has current market cap of $97M, and enterprise value of $92M.

Actinogen Medical's stock price is $0.03.

Actinogen Medical Valuation Multiples

Actinogen Medical trades at 28.8x EV/Revenue multiple, and (7.3x) EV/EBITDA.

Actinogen Medical Financial Valuation Multiples

As of April 15, 2026, Actinogen Medical has market cap of $97M and EV of $92M.

Equity research analysts estimate Actinogen Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Actinogen Medical has a P/E ratio of (7.7x).

Actinogen Medical Margins & Growth Rates

Actinogen Medical's revenue in the last 12 month grew by 357%.

Actinogen Medical's rule of 40 is 277% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Actinogen Medical's rule of X is 861% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Actinogen Medical Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Actinogen Medical M&A Activity

Actinogen Medical acquired XXX companies to date.

Last acquisition by Actinogen Medical was on XXXXXXXX, XXXXX. Actinogen Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Actinogen Medical Investment Activity

Actinogen Medical invested in XXX companies to date.

Actinogen Medical made its latest investment on XXXXXXXX, XXXXX. Actinogen Medical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).